US EditionCARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
- On May 11, 2025, CARsgen Therapeutics revealed initial results from an early-stage study in Shanghai evaluating CT0596, an off-the-shelf CAR-T therapy targeting BCMA.
- The study evaluates CT0596, developed with the THANK-u Plus platform, in relapsed/refractory multiple myeloma or plasma cell leukemia patients following lymphodepletion.
- Eight patients with at least three prior therapy lines received CT0596 with no dose-limiting toxicities, grade 3 CRS, ICANS, or graft-versus-host disease reported.
- Among five patients assessed at Week 4, 60% achieved complete response and 80% reached minimal residual disease negativity, with CAR-T expansion observed during follow-up.
- These preliminary safety and efficacy results support further exploration in multiple myeloma and related diseases, with an IND application planned for the second half of 2025.
74 Articles
74 Articles
Targeting inflammation with chimeric antigen receptor macrophages using a signal switch
Chimeric antigen receptor (CAR) T-cell immunotherapy has shown great success in clinical cancer, bringing hope to apply CAR strategies to other clinical settings. Here we developed a CAR macrophage (CAR-M) that recognizes the major inflammatory molecule tumour necrosis factor (TNF) and activates an intracellular IL-4 signalling pathway, thereby programming engineered macrophages for an anti-inflammatory function. CAR-M therapy has exhibited effi…
Daily News-Record
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596, an allogeneic BCMA-targeted CAR-T developed using the THANK-u Plus™ platform. CT0596 is…
Coverage Details
Bias Distribution
- 65% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
